In the realm of modern medicine, RNA-based therapies have emerged as a promising avenue, with significant advancements in metabolic diseases, oncology, and preventive vaccines. A recent article ...

In this article, we examine ongoing challenges shaping target-based drug discovery and highlight how new technologies and ...

This process is costly, time-consuming, and has a low success rate. KAIST researchers have developed an AI model that, using only information about the target protein, can design optimal drug ...

TOKYO--(BUSINESS WIRE)--Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”) is pleased to announce that its AI drug discovery platform, Elix ...

Scientists led by a team at the Medical Research Council (MRC) Mitochondrial Biology Unit, University of Cambridge, have worked out how a molecular machine found in mitochondria—the “powerhouses” of ...

Artificial intelligence (AI)-based drug developer Isomorphic Labs said it has raised $600 million in its first external funding round, with the proceeds expected to accelerate its research and ...

An illustration of an algorithm predicting a protein structure, with digitized blocks on the left becoming ribbons on the right. An illustration of the RoseTTAFold software predicting a protein ...

SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a foc ...

Structure Therapeutics Inc. has announced the selection of its lead oral small molecule amylin receptor agonist, ACCG-2671, which shows promising preclinical results including potent target engagement ...